Is OGN or OKUR more undervalued in 2026?

CirclFi compares Organon & Co. (OGN) and OnKure Therapeutics, Inc. (OKUR) using 13 institutional-grade valuation models. OGN has a Quality of Company score of 7.5/10 while OKUR scores 5.6/10.

Which is a better buy — OGN or OKUR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OGN and OKUR valuations compare?

OGN at $13.34 and OKUR at $4.20 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OGN vs OKUR Valuation Comparison 2026 — Intrinsic Value Analysis

OGN

Pharmaceutical Preparations

Organon & Co.

Quality

7.5

out of 10

Value Trap

LOW

Price

$13.34

Last close

Models

12/13

Active

OKUR

Pharmaceutical Preparations

OnKure Therapeutics, Inc.

Quality

5.6

out of 10

Value Trap

LOW

Price

$4.20

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	OGN Fair Value	OGN Upside	OKUR Fair Value	OKUR Upside
Bayesian DCF	Intrinsic	$6.77	-49.2%	$3.02	-28.2%
Earnings Power Value	Intrinsic	$8.09	-39.2%	$7.86	+66.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OGN vs OKUR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OGN vs OKUR — Which Stock Is More Undervalued?

OGN scores higher with a 7.5/10 quality rating vs OKUR's 5.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Organon & Co. (OGN) and OnKure Therapeutics, Inc. (OKUR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OGN currently trades at $13.34 with a QOC of 7.5/10, while OKUR trades at $4.20 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).